Patent US4954474A successfully refreshed from Google Patents.
Patent EP0601585A2 successfully refreshed from Google Patents.
EP0601585A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Nucleic acid construct for inhibiting or regulating the functions of an immuno response gene, method utilizing the same and immunologically compatible system containing the same
Assignee: Enzo Therapeutics Inc
•
Filing: 1993-12-09
•
Granted: —
•
Expires: 2013-12-09
Abstract
Abstract This invention provides a method for preparing an immunologically compatible system, e.g., organism, organ, tissue, or cells, by appropriate genetic intervention which can take the form of introducing into the cells of such a system, a nucleic acid construct which, when present in a cell, inhibits or regulates the function of an immune response (Ir) gene or genes in the system. The nucleic acid construct can be introduced, for example, in the form of genetic antisense or as antisense oligos. Also provided by the present invention is such a nucleic acid construct and an immunologically compatible system containing such a nucleic acid construct. When present in a cell, the nucleic acid construct inhibits or regulates the function of an immune response gene or genes in the system. This invention is useful and applicable in the field of therapeutics, and transplantation and transfusion methodologies.
Inventors
- 👤 Elazar Rabbani
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-07 08:23
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/113; C12N15/1138; C12N15/63; C12N15/79; C12N15/85; C12N15/8509; A; A01; A01K; A01K2207/00; A01K2207/15; A01K2217/00; A01K2217/05; A01K2217/07; A01K2217/075; A01K2267/00; A01K2267/02; A01K2267/025; A01K2267/03; A01K2267/035; A01K2267/0381; C12N2310/00; C12N2310/10; C12N2310/11; C12N2310/111
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
23 words
A nucleic acid construct which, when present in a cell, inhibits or regulates the function of an immune response gene in a system.
Claim 2
Dependent Claim
44 words
The nucleic acid construct according to claim 1 therein containing (a) a nucleic acid segment that produces a nucleic acid sequence complementary to at least a portion of a ribonucleotide sequence transcribed from said gene, to inhibit or regulate the function of said gene.
Claim 3
Dependent Claim
29 words
The nucleic acid construct according to claim 2 further comprising (b) a transcriptional promoter segment, and (c) a transcription termination segment; and said (a) nucleic acid segment is therebetween.
Claim 4
Dependent Claim
25 words
The nucleic acid construct according to claim 1 comprising an oligonucleotide complementary to at least a portion of the ribonucleotide sequence transcribed from said gene.
Claim 5
Dependent Claim
25 words
The nucleic acid construct according to claim 1 comprising a plurality of oligonucleotides complementary to different portions of the ribonucleotide sequence transcribed from said gene.
Claim 6
Dependent Claim
47 words
The nucleic acid construct according to claims 4 or 5 wherein said complementary oligonucleotides comprise at least one modified member selected from the group consisting of an association constant increasing modifier, an association increasing modifier, and an intercalating agent, or a combination of any of the foregoing.
Claim 7
Dependent Claim
20 words
The nucleic acid construct according to claim 1 wherein said immune response gene is part of the major histocompatibility complex.
Claim 8
Dependent Claim
20 words
An immunologically compatible system containing a nucleic acid construct according to any one of claims 1 to 3 and 7.
Claim 9
Dependent Claim
31 words
The immunologically compatible system according to claim 8 comprising at least one member selected from the group consisting of an organism, an organ, a tissue, and cells, or a combination thereof.
Claim 10
Dependent Claim
17 words
The immunologically compatible system according to claim 9 wherein said organism, organ, tissue, or cells are mammalian.
Claim 11
Dependent Claim
20 words
The immunologically compatible system according to claim 10 wherein said mammalian organism, organ, tissue, or cells are simian or porcine.
Claim 12
Independent Claim
34 words
A method for rendering a system immunologically compatible, said method comprising the step of introducing into the cells of said system a nucleic acid construct according to any one of claims 1 to 7.
Claim 13
Dependent Claim
22 words
The method according to claim 12 wherein said immunologically compatible system is defined according to any one of claims 9 to 11.
Claim 14
Dependent Claim
23 words
The method according to claim 12 wherein said introducing step is carried out with a vector having incorporated therein said nucleic acid construct.
Claim 15
Dependent Claim
15 words
The method according to claim 14 wherein said vector is a plasmid or a virus.
Claim 16
Dependent Claim
26 words
The method according to claim 12 wherein said introducing step is carried out with a delivery system for delivering said nucleic acid construct to said cell.
Claim 17
Independent Claim
55 words
A method for rendering a system immunologically compatible, said method comprising the steps of introducing into embryonic mammalian cells a nucleic acid construct which, when present in a cell, inhibits or regulates the function of an immune response gene in said system; and thereafter allowing said cells to develop into a mature immunologically compatible system.
Claim 18
Dependent Claim
32 words
The method according to claim 17 wherein said immunologically compatible system comprises a member selected from the group consisting of an organism, an organ, a tissue or cells, or any combination thereof.
References Cited (Backward Citations)
US5190931A
Cited
US4736866A
Cited
US4736866B1
Cited
WO1991015503A1
Cited
WO1993014769A1
Cited
WO1993021202A1
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.